Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.67 |
| ▸ | FPR2 | P25090 | 5/20 | 0.66 |
| ▸ | FPR1 | P21462 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486127 | 0.92 | F10 (0.65) | F10FPR2FPR1 | |
| SCHEMBL4485882 | 0.88 | FPR2 (0.69) | F10FPR2FPR1 | |
| SCHEMBL20555885 | 0.84 | FPR2 (0.77) | F10FPR2FPR1 | |
| SCHEMBL18955218 | 0.84 | FPR2 (0.77) | F10FPR2FPR1 | |
| SCHEMBL4491912 | 0.84 | F10 (0.70) | F10FPR2FPR1 | |
| SCHEMBL4491905 | 0.82 | FPR2 (0.71) | F10FPR2FPR1 | |
| SCHEMBL4681099 | 0.82 | F10 (0.85) | F10FPR2FPR1 | |
| SCHEMBL30133742 | 0.81 | F10 (0.72) | F10FPR2FPR1 | |
| SCHEMBL30337924 | 0.81 | F10 (0.72) | F10FPR2FPR1 | |
| SCHEMBL4684779 | 0.81 | F10 (0.85) | F10FPR2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | claimed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | SMALLHEER JOANNE M | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, F5 | F10 38/4885FPR2 3867/4885FPR1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.